Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
基本信息
- 批准号:10434654
- 负责人:
- 金额:$ 69.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-04-04 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Absence of pain sensationAcuteAcute PainAttenuatedBiological AvailabilityBiologyBloodBlood CirculationBlood VesselsChronicClinical TrialsCytoplasmic GranulesDNADataDefectEndotheliumErythrocytesFDA approvedFrightGeneticGoalsHemeHeme IronHemoglobinHemolysisHereditary DiseaseHistonesHospitalizationHumanHyperalgesiaIn VitroIndividualInflammationInflammatoryInjuryLaboratoriesLeadLifeMediatingMicrovascular DysfunctionMusNerveNervous system structureNeurogenic InflammationNeuronsNuclearOpioidOxidative StressPainPatientsPeptide HydrolasesPersonsPharmaceutical PreparationsPharmacologyPlayPoint MutationPorphyrinsProcessQuality of lifeRecurrenceRoleSickle CellSickle Cell AnemiaSickle Cell TraitSickle HemoglobinSourceStimulusSystemTLR4 geneTNF geneTestingTissuesTransgenic OrganismsTranslationsTryptaseVascular DiseasesVascular Permeabilitiesaddictionaxon injurybasechronic paincongeniccytokinecytotoxicdebilitating painendoplasmic reticulum stressextracellularfunctional outcomesgranulocytehemoglobin AAimprovedin vivoinfancyinhibitormast cellmouse modelmultidisciplinaryneuroinflammationneurotransmissionneurovascularnovelopioid useparoxysmal nocturnal hemoglobinuriapathogenpreventrelating to nervous systemresponsesicklingside effecttranslational approachvascular injuryvaso-occlusive crisisvaso-occlusive pain
项目摘要
Summary/Abstract
Sickle cell disease (SCD), a recessive inherited disorder caused by a point mutation in the hemoglobin chain of
red blood cells (RBCs). Microvascular dysfunction is central to the pathobiology of SCD, leading to life-
threatening consequences. A major consequence is occlusion of activated microvasculature with sickle RBCs
leading to unpredictable and frequent episodes of acute pain called vaso-occlusive crises (VOC), frequent
hospitalization and poor quality of life. Many individuals with SCD suffer chronic pain that may start during
infancy and continue to increase throughout life. Opioids are the mainstay for treatment but their side-effects
and fear of addiction remain a major concern. Hence, a major unmet need is to prevent and/or treat pain more
effectively. VOC is associated with increased hemolysis that releases free heme. Our preliminary data reveal
that administration of free heme causes hyperalgesia (pain) in transgenic sickle mice expressing human sickle
hemoglobin (Hb) and in control mice expressing normal human HbA. Our preliminary data shows that heme
stimulates mast-cell extracellular traps (ETs) by releasing nuclear DNA and citrullinated histones. Mast-
cell activation promotes hyperalgesia in sickle mice. We hypothesize that heme-induced mast-cell
activation leads to release of citrullinated histones and noxious substances and contributes to
inflammation, vascular dysfunction and axonal injury leading to vasoocclusion and hyperalgesia in
SCD (Schema I). Mast cells may play a causal role in VOC and chronic pain in SCD. Targeting mast cells
will ameliorate VOC and pain at its source. We will test our hypothesis using a translational approach with
four specific aims to establish whether, heme contributes to chronic and/or acute hyperalgesia (Aim1),
heme contributes to chronic/acute pain via mast-cell activation (Aim2), and heme-induced hyperalgesia
is driven by novel mast cell–dependent mechanisms leading to axonal and vascular injury (Aim3),
including, release of inflammatory cytokines, proteases, ETs with DNA and citrullinated histones from mast
cells that cause axonal injury in the periphery and DRG neurons, and endothelial activation via endoplasmic
reticulum stress. Aim4 will entail determining whether targeting the mechanisms of heme-induced mast-
cell activation attenuates hyperalgesia and vaso-occlusion. We will use genetic and pharmacological
approaches, namely [i] humanized transgenic HbSS-BERK sickle mice exclusively expressing human sickle
Hb, [ii] HbAA-BERK control mice expressing normal human HbA, [iii] sickle mice deleted for, [a] mast cells or
[b] TLR4 and their congenic controls; and mechanism-specific pharmacological inhibitors to prevent vaso-
occlusion and pain. Mouse models and biologicals are available in our laboratories. By using multiple
strategies in vivo and in vitro, involving mast cell–mediated hyperalgesia and their targeting with novel
and/or FDA-approved drugs, we expect that our observations will lead to translationally relevant
functional outcomes—reduction of VOC and acute as well as chronic pain in SCD.
总结/摘要
镰状细胞病(SCD)是一种隐性遗传性疾病,由血红蛋白链的点突变引起,
红细胞(RBC)。微血管功能障碍是SCD病理学的核心,导致生命-
威胁的后果。一个主要的后果是闭塞的激活微血管与镰状红细胞
导致不可预测和频繁发作的急性疼痛,称为血管闭塞性危象(VOC),
住院和生活质量差。许多患有SCD的个体遭受慢性疼痛,这些疼痛可能始于
婴儿期,并在整个生命中继续增加。阿片类药物是治疗的主要药物,但其副作用
以及对上瘾的恐惧仍然是一个主要问题。因此,一个主要的未满足的需求是预防和/或治疗疼痛,
有效地VOC与释放游离血红素的溶血增加有关。我们的初步数据显示
游离血红素的施用在表达人镰状细胞的转基因镰状细胞小鼠中引起痛觉过敏(疼痛
血红蛋白(Hb)和表达正常人HbA的对照小鼠。我们的初步数据显示血红素
通过释放核DNA和瓜氨酸化组蛋白刺激肥大细胞胞外陷阱(cytotoxictraps,cytotoxictraps)。桅杆-
细胞活化促进镰状小鼠的痛觉过敏。我们假设血红素诱导的肥大细胞
激活导致瓜氨酸化组蛋白和有毒物质的释放,
炎症,血管功能障碍和轴突损伤导致血管闭塞和痛觉过敏,
SCD(模式I)。肥大细胞可能在SCD的VOC和慢性疼痛中发挥因果作用。靶向肥大细胞
将从源头上改善VOC和疼痛。我们将使用翻译方法测试我们的假设,
四个具体目标是确定血红素是否有助于慢性和/或急性痛觉过敏(Aim 1),
血红素通过肥大细胞激活(Aim2)和血红素诱导的痛觉过敏促进慢性/急性疼痛
是由新的肥大细胞依赖性机制驱动的,导致轴突和血管损伤(Aim3),
包括从肥大细胞释放炎性细胞因子、蛋白酶、DNA和瓜氨酸化组蛋白,
引起外周和DRG神经元轴突损伤的细胞,以及通过内质网激活内皮细胞
网状应激Aim4将需要确定是否靶向血红素诱导的肥大细胞的机制,
细胞活化减弱痛觉过敏和血管闭塞。我们将使用遗传学和药理学
方法,即[i]人源化转基因HbSS-BERK镰状小鼠,仅表达人镰状细胞
Hb,[ii]表达正常人HbA的HbAA-BERK对照小鼠,[iii]缺失的镰状小鼠,[a]肥大细胞或
[b]TLR4及其同类对照;以及预防血管紧张素Ⅱ的机制特异性药理学抑制剂。
闭塞和疼痛。我们的实验室提供小鼠模型和生物制剂。通过使用多个
在体内和体外的策略,涉及肥大细胞介导的痛觉过敏和他们的目标与新的
和/或FDA批准的药物,我们希望我们的观察将导致与临床相关的
功能结局-减少VOC和SCD中的急性及慢性疼痛。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kalpna Gupta其他文献
Kalpna Gupta的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kalpna Gupta', 18)}}的其他基金
Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
- 批准号:
10207087 - 财政年份:2021
- 资助金额:
$ 69.37万 - 项目类别:
Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
- 批准号:
10377411 - 财政年份:2021
- 资助金额:
$ 69.37万 - 项目类别:
Summer Mentoring and Research Training (SMART)
暑期指导和研究培训(SMART)
- 批准号:
10614485 - 财政年份:2021
- 资助金额:
$ 69.37万 - 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
- 批准号:
10076288 - 财政年份:2020
- 资助金额:
$ 69.37万 - 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
- 批准号:
10424765 - 财政年份:2019
- 资助金额:
$ 69.37万 - 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
- 批准号:
9906937 - 财政年份:2019
- 资助金额:
$ 69.37万 - 项目类别:
Targeting mechanisms contributing to vascular dysfunction and pain in sickle cell disease
导致镰状细胞病血管功能障碍和疼痛的靶向机制
- 批准号:
10095111 - 财政年份:2019
- 资助金额:
$ 69.37万 - 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
- 批准号:
8467856 - 财政年份:2013
- 资助金额:
$ 69.37万 - 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
- 批准号:
8722605 - 财政年份:2013
- 资助金额:
$ 69.37万 - 项目类别:
Cannabinoid-based therapy and approaches to quantify pain in sickle cell disease
基于大麻素的疗法和量化镰状细胞病疼痛的方法
- 批准号:
8877627 - 财政年份:2013
- 资助金额:
$ 69.37万 - 项目类别:
相似海外基金
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10778757 - 财政年份:2023
- 资助金额:
$ 69.37万 - 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
- 批准号:
10603436 - 财政年份:2023
- 资助金额:
$ 69.37万 - 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
- 批准号:
10783106 - 财政年份:2023
- 资助金额:
$ 69.37万 - 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
- 批准号:
10740796 - 财政年份:2023
- 资助金额:
$ 69.37万 - 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
- 批准号:
10599401 - 财政年份:2022
- 资助金额:
$ 69.37万 - 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
- 批准号:
575854-2022 - 财政年份:2022
- 资助金额:
$ 69.37万 - 项目类别:
Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
- 批准号:
467076 - 财政年份:2021
- 资助金额:
$ 69.37万 - 项目类别:
Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
9979265 - 财政年份:2020
- 资助金额:
$ 69.37万 - 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
- 批准号:
10218273 - 财政年份:2020
- 资助金额:
$ 69.37万 - 项目类别: